This study provides evidence that genetic variants of immunodeficiency pathway-related genes, especially TNFRSF13B, contribute to prostate cancer recurrence through modulating the cell cycle and p53 signalling pathways (Fig. 6). This evidence concerns the gene TP53 and prostate carcinoma.